Amyloidogenic propensity of a natural variant of human apolipoprotein A-I: Stability and interaction with ligands

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Rosú, Silvana A ^a,b   Rimoldi, Omar J ^a,b   Prieto, Eduardo D ^a,c   Curto, Lucrecia M ^d   Delfino, José M ^d   Ramella, Nahuel A ^a,b   Tricerri, M Alejandra ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

^c INSTITUTO DE INVESTIGACIONES FISICOQUÍMICAS TEÓRICAS Y APLICADAS INIFTA   (Argentina)

^d UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PROTEIN; APOLIPOPROTEIN A1; DODECYL SULFATE SODIUM; ARGININE; HEPARIN; PHOSPHOLIPID; PROLINE; PROTEIN AGGREGATE; PROTEIN BINDING;

ACIDITY; AMYLOIDOSIS; ARTICLE; HUMAN; HYDROPHOBICITY; LIGAND BINDING; LIPID SOLUBILITY; PH; POINT MUTATION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STABILITY; PROTEIN STRUCTURE; TRANSITION TEMPERATURE; CHEMISTRY; GENETICS; METABOLISM; MOLECULAR MODEL;

AMYLOIDOGENIC PROTEINS; APOLIPOPROTEIN A-I; ARGININE; HEPARIN; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; PHOSPHOLIPIDS; POINT MUTATION; PROLINE; PROTEIN AGGREGATES; PROTEIN BINDING; PROTEIN STABILITY; SODIUM DODECYL SULFATE;

EID: 84929224748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124946     Document Type: Article

References (49)

1. Bellotti V, Mangione P, Stoppini M (1999) Biological activity and pathological implications of misfolded proteins. Cell Mol Life Sci 55: 977-991. PMID: 10412375
2. Dember LM (2006) Amyloidosis-associated kidney disease. J Am Soc Nephrol 17: 3458-3471. PMID: 17093068
3. Saraiva MJ (2001) Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett 498: 201-203. PMID: 11412857
4. Schaefer EJ, Anthanont P, Asztalos BF (2014) High-density lipoprotein metabolism, composition, function, and deficiency. Curr Opin Lipidol 25: 194-199. doi: 10.1097/MOL.0000000000000074 PMID: 24785961
5. Rye KA, Barter PJ (2004) Formation and metabolism of prebeta-migrating, lipid-poor apolipoprotein AI. Arterioscler Thromb Vasc Biol 24: 421-428. PMID: 14592845
6. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. (2004) Antiinflammatory properties of HDL. Circ Res 95: 764-772. PMID: 15486323
7. Curtiss LK, Valenta DT, Hime NJ, Rye KA (2006) What is so special about apolipoprotein AI in reverse cholesterol transport? Arterioscler Thromb Vasc Biol 26: 12-19. PMID: 16269660
8. Eriksson M, Schonland S, Yumlu S, Hegenbart U, von Hutten H, Gioeva Z, et al. (2009) Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn 11: 257-262. doi: 10.2353/jmoldx.2009.080161 PMID: 19324996
9. Mucchiano GI, Haggqvist B, Sletten K, Westermark P (2001) Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 193: 270-275. PMID: 11180176
10. Obici L, Franceschini G, Calabresi L, Giorgetti S, Stoppini M, Merlini G, et al (2006) Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13: 191-205. PMID: 17107880
11. Raimondi S, Guglielmi F, Giorgetti S, Di Gaetano S, Arciello A, Monti DM, et al.(2011) Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I. J Mol Biol 407: 465-476. doi: 10.1016/j.jmb.2011.01.044 PMID: 21296086
12. Nichols WC, Gregg RE, Brewer HB Jr, Benson MD (1990) A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 8: 318-323. PMID: 2123470
13. Ramella NA, Schinella GR, Ferreira ST, Prieto ED, Vela ME, Rios JL et al. (2012) Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity. PLoS One 7: e43755. doi: 10.1371/journal.pone.0043755 PMID: 22952757
14. Hamidi Asl K, Liepnieks JJ, Nakamura M, Parker F, Benson MD (1999) A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis. Biochem Biophys Res Commun 257: 584-588. PMID: 10198255
15. Ramella NA, Rimoldi OJ, Prieto ED, Schinella GR, Sanchez SA, Jaureguiberry MS, et al. (2011) Human apolipoprotein A-I-derived amyloid: its association with therosclerosis. PLoS One 6: e22532. doi: 10.1371/journal.pone.0022532 PMID: 21811627
16. Prieto ED, Ramella N, Cuellar LA, Tricerri MA, Garda HA (2012) Characterization of a human apolipoprotein a-I construct expressed in a bacterial system. Protein J 31: 681-688. doi: 10.1007/s10930-012-9448-z PMID: 22986928
17. Gomori G (1955) Preparation of Buffers for Use in Enzyme Studies. Methods Enzymol 1: 138-146.
18. Chapeaurouge A, Johansson JS, Ferreira ST (2002) Folding of a de novo designed native-like four-helix bundle protein. J Biol Chem 277: 16478-16483. PMID: 11832477
19. Martins SM, Chapeaurouge A, Ferreira ST (2003) Folding intermediates of the prion protein stabilized by hydrostatic pressure and low temperature. J Biol Chem 278: 50449-50455. PMID: 14525996
20. Monsellier E, Bedouelle H (2005) Quantitative measurement of protein stability from unfolding equilibria monitored with the fluorescence maximum wavelength. Protein Eng Des Sel 18: 445-456. PMID: 16087653
21. Lakowicz JR (1986) Principles of fluorescence spectroscopy; Press P, editor. New York.
22. Botelho MG, Gralle M, Oliveira CL, Torriani I, Ferreira ST (2003) Folding and stability of the extracellular domain of the human amyloid precursor protein. J Biol Chem 278: 34259-34267. PMID: 12796495
23. Chapeaurouge A, Johansson JS, Ferreira ST (2001) Folding intermediates of a model three-helix bundle protein. Pressure and cold denaturation studies. J Biol Chem 276: 14861-14866. PMID: 11278529
24. Schmid F (1989) Protein Structure: a practical approach; IRL, editor. New York: Creighton, T.E.
25. Shi Y, Fan DJ, Li SX, Zhang HJ, Perrett S, Zhou JM (2007) Identification of a potential hydrophobic peptide binding site in the C-terminal arm of trigger factor. Protein Sci 16: 1165-1175. PMID: 17525465
26. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254. PMID: 942051
27. Tricerri MA, Behling Agree AK, Sanchez SA, Bronski J, Jonas A (2001) Arrangement of apolipoprotein A-I in reconstituted high-density lipoprotein disks: an alternative model based on fluorescence resonance energy transfer experiments. Biochemistry 40: 5065-5074. PMID: 11305923
28. Hawe A, Sutter M, JiskootW(2008) Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res 25: 1487-1499. doi: 10.1007/s11095-007-9516-9 PMID: 18172579
29. LeVine H III (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 309: 274-284. PMID: 10507030
30. Pertinhez TA, Bouchard M, Smith RA, Dobson CM, Smith LJ (2002) Stimulation and inhibition of fibril formation by a peptide in the presence of different concentrations of SDS. FEBS Lett 529: 193-197. PMID: 12372599
31. Kihara M, Chatani E, Sakai M, Hasegawa K, Naiki H, Goto Y (2005) Seeding-dependent maturation of beta2-microglobulin amyloid fibrils at neutral pH. J Biol Chem 280: 12012-12018. PMID: 15659393
32. Sorci-Thomas MG, Thomas MJ (2002) The effects of altered apolipoprotein A-I structure on plasma HDL concentration. Trends Cardiovasc Med 12: 121-128. PMID: 12007737
33. Souillac PO, Uversky VN, Millett IS, Khurana R, Doniach S, Fink AL (2002) Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH. J Biol Chem 277: 12657-12665. PMID: 11815605
34. Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, et al. (1997) Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385: 787-793. PMID: 9039909
35. Hammarstrom P, Sekijima Y, White JT, Wiseman RL, Lim A, Costello CE, et al. (2003) D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Biochemistry 42: 6656-6663. PMID: 12779320
36. Das M, Mei X, Jayaraman S, Atkinson D, Gursky O (2014) Amyloidogenic mutations in human apolipoprotein A-I are not necessarily destabilizing-a common mechanism of apolipoprotein A-I misfolding in familial amyloidosis and atherosclerosis. Febs J 281: 2525-2542. doi: 10.1111/febs.12809 PMID: 24702826
37. Gursky O, Mei X, Atkinson D (2011) The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment. Biochemistry 51: 10-18. doi: 10.1021/bi2017014 PMID: 22229410
38. Adachi E, Kosaka A, Tsuji K, Mizuguchi C, Kawashima H, Shigenaga A, et al. (2013) The extreme N-terminal region of human apolipoprotein A-I has a strong propensity to form amyloid fibrils. FEBS Lett 588: 389-394. doi: 10.1016/j.febslet.2013.11.031 PMID: 24316228
39. Mendoza-Espinosa P, Montalvan-Sorrosa D, Garcia-Gonzalez V, Moreno A, Castillo R, Mas-Oliva J (2014) Microenvironmentally controlled secondary structure motifs of apolipoprotein A-I derived peptides. Mol Cell Biochem 393: 99-109. doi: 10.1007/s11010-014-2050-2 PMID: 24748322
40. Arnulphi C, Sanchez SA, Tricerri MA, Gratton E, Jonas A (2005) Interaction of human apolipoprotein AI with model membranes exhibiting lipid domains. Biophys J 89: 285-295. PMID: 15849246
41. van der Goot FG, Gonzalez-Manas JM, Lakey JH, Pattus F (1991) A 'molten-globule' membrane-insertion intermediate of the pore-forming domain of colicin A. Nature 354: 408-410. PMID: 1956406
42. Ahmad MF, Ramakrishna T, Raman B, Rao CM (2006) Fibrillogenic and non-fibrillogenic ensembles of SDS-bound human alpha-synuclein. J Mol Biol 364: 1061-1072. PMID: 17054982
43. Roman EA, Rosi P, Gonzalez Lebrero MC, Wuilloud R, Gonzalez Flecha FL, Delfino JM (2010) Gain of local structure in an amphipathic peptide does not require a specific tertiary framework. Proteins 78: 2757-2768. doi: 10.1002/prot.22789 PMID: 20607854
44. Cohlberg JA, Li J, Uversky VN, Fink AL (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry 41: 1502-1511. PMID: 11814343
45. Noborn F, O'Callaghan P, Hermansson E, Zhang X, Ancsin JB, Damas AM, et al. (2011) Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein. Proc Natl Acad Sci U S A 108: 5584-5589. doi: 10.1073/pnas.1101194108 PMID: 21422279
46. Kinsella MG, Bressler SL, Wight TN (2004) The regulated synthesis of versican, decorin, and biglycan: extracellular matrix proteoglycans that influence cellular phenotype. Crit Rev Eukaryot Gene Expr 14: 203-234. PMID: 15248816
47. Shirk RA, Parthasarathy N, San Antonio JD, Church FC, Wagner WD (2000) Altered dermatan sulfate structure and reduced heparin cofactor II-stimulating activity of biglycan and decorin from human atherosclerotic plaque. J Biol Chem 275: 18085-18092. PMID: 10749870
48. Rasente RY, Egitto P, Calabrese GC (2012) Low molecular mass dermatan sulfate modulates endothelial cells proliferation and migration. Carbohydr Res 356: 233-237. doi: 10.1016/j.carres.2012.03.036 PMID: 22533918
49. Iannuzzi C, Irace G, Sirangelo I (2015) The Effect of Glycosaminoglycans (GAGs) on Amyloid Aggregation and Toxicity. Molecules 20: 2510-2528. doi: 10.3390/molecules20022510 PMID: 25648594